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China has entered the era of obesity. Data
from China Noncommunicable Disease
(NCD) Surveillance 2010 have shown that
one in three Chinese adults had either
central or general obesity. Meanwhile, the
epidemic of childhood obesity may weigh
on China’s future. Obesity affects virtually
all ages and socioeconomic groups and
significantly contributes to the rocket-rising
incidence of NCDs, including type 2 dia-
betes,cardiovasculardiseases,andcertain
forms of cancer, which is worrisome for a
country with a population of 1.37 billion.
The huge demographic pressure, unbal-
anced economic development, unmet
social diversity, and childhood obesity
epidemic have all created tough chal-
lenges for the Chinese government to
fight against obesity. Prevention and con-
trol strategies must be comprehensive
and should include proactive approaches:
reducing health disparity through health-
care reform and development, protecting
parental and childhood health, enhancing
education on a healthy lifestyle, imple-
menting awareness and detection pro-
grams for genetically susceptible indi-
viduals, and early interventions targeting
high-risk population. To efficiently halt the
obesity epidemic, the main focus should
be placed on children and adolescents.
The national research supporting systems
should encourage biomedical scientists
to explore the pathogenesis of obesity
and develop safe and effective novel
anti-obesity drugs/procedures toward gut
microbes, brown fat, and genetic targets
in regulatory network of metabolism.
International cooperation is of key impor-
tance in basic research and translational
studies. It is tough, but with hope.Move It and Lose It
Juleen Zierath
Karolinska Institutet
There is a growing health burden arising
from the interrelated sequelae of meta-
bolic disorders comprising impaired
glucose tolerance, type 2 diabetes, and
sarcopenia. Obesity and physical inac-
tivity are the main drivers of these meta-
bolic disorders, with the risk of co-morbid-
ities including hypertension, dyslipidemia,
cardiovascular disease, stroke, cancer,
sleep apnea, gallbladder disease, hyper-
uricemia and gout, and osteoarthritis.
A critical health issue facing overweight
adults is how to lose fat mass and improve
whole-body glucose tolerance, while
simultaneously preserving skeletal mus-
cle mass. This goal is made especially
difficult in the face of reduced levels of
physical activity and increased longevity.
Modifiable lifestyle factors such as exer-
cise training and diet are clinically proven,
cost-effective, primary interventions that
delayand, inmanycases,prevent thehealth
burdens associated with obesity. Yet,
achieving this is easier said than done, and
inertia is difficult to overcome. The principal
challenge is to find ‘‘practical, ready-to-
use’’ solutions to combat the growing epi-
demic-like increase in metabolic disease.
This could be through the development of
time-efficient, lifelong exercise intervention
strategies that include dietary modifica-
tions. Importantly, these modifications
must be readily incorporated intoan individ-
ual’s ‘‘everyday routine.’’Asecondgoal is to
provide clinical insight into the heterogene-
ity underlying not only the development
of metabolic disease, but also individual
differences in the response to treatment
regimes. Given the widespread benefits
of regular physical activity, it may be better
to be fit and fat than lean and lethargic.Cell 16Research, Not Surgery
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As a physician-researcher in the field
of diabetes and obesity, I am struck
each year by the statistics showing the
increasing prevalence of overweight and
obesity and one of its major results, type
2 diabetes, with almost a million more
cases each year in the U.S. alone. At the
same time, I am struck by the great ad-
vances in research on cellular/molecular
mechanisms underlying the control of
energy balance through regulation of
appetite and energy expenditure. The
data are clear that the driving force in
this epidemic is increasing levels of
energy intake (168–335 kcal/day between
1970 and 2000), coupled with decreasing
energy expenditure due to sedentary life-
style. As one of my obese patients said,
‘‘Doc, I am digging my grave with my
mouth.’’ How are we going to change
this trajectory? History has shown that
changing behavior is difficult. Bariatric
surgery works, but even in the best cen-
ters, surgical mortality rates are about 1
per 1,000—a level higher than we would
ever accept for a medical therapy. So we
have to find ways to convert our research
into practical solutions. There are at least
three areas of real hope: (1) unleashing
the power of anorexigenic hormones,
including hypothalamic, adipose-derived,
and gut hormones; (2) stoking the fire of
energy expenditure through agents that
activate or increase the mass of brown/
beige fat; and (3) finding the composition
of gut microbiota that minimizes the
impact of caloric excess on weight gain,
insulin resistance, and metabolic dys-
function. With these, we can begin to
stem the rising tide of obesity and its
associated metabolic complications.1, March 26, 2015 ª2015 Elsevier Inc. 173
Fat Is Not Your Enemy!
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Obesity is defined as a condition of
excessive fat mass, but what do the
fat cells do in normal physiology and in
pathological states like obesity? White
adipose tissue (ordinary fat) represents
the major site for storage of chemical
energy in mammals. When there is an
imbalance between energy intake (eating)
and energy expenditure (exercise, normal
cellular processes, and thermogenesis),
most of that excess energy is stored as
triglycerides in fat. This is the proper
and healthy place for energy storage, as
lipid deposition in non-adipose tissues
such as liver or muscle can impair their
function. This occurs with adipose cell
dysfunction (lipodystrophy) or when the
excess energy simply overtakes the ca-
pacity of the fat to store those calories,
as in many obese humans. A critical idea
that emerged in the 1980s–90s was that
adipose tissues are a critical ‘‘information
hub’’ and signal metabolic status to
the rest of the body through secretion of
‘‘adipokines,’’ such as TNF-a, leptin,
adipsin, and adiponectin. These affect
insulin sensitivity, feeding behavior, and
b cell function.
Recently, much attention has been
focused on brown and beige adipocytes,
thermogenic cells that exist in both ro-
dents and humans. These cells dissipate
chemical energy in the form of heat
via uncoupled respiration. Increases in
amounts of brown and beige fat have
been shown to protect against obesity
and diabetes in rodent models; strenuous
efforts are now being undertaken to learn
how to expand or activate these depots
in ways that might be therapeutic in
humans.174 Cell 161, March 26, 2015 ª2015 ElsevierThe Secrets of Outliers
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Successful efforts in obesity prevention
will require major changes to the obeso-
genic environment that will be easier to
enact in some societies than others for
cultural and political reasons. Even with
such changes, however, there will still be
some individuals who are susceptible to
morbid obesity and others who develop
catastrophic metabolic decompensation.
To treat these people, we will need
improved medicines. A foothold toward
improved therapeutics has come from
studies of human outliers who carry highly
penetrant mutations. These studies have
been enormously helpful in providing a
‘‘wiring diagram’’ for how processes
such as energy balance or the mainte-
nance of insulin sensitivity are regulated
in humans. In metabolic disease, there
are powerful recent examples of how the
discovery of the causative genetic defect
in very rare outliers for phenotypes such
as bone density or serum cholesterol
has directly led to the development of
exciting therapeutics. In the area of
obesity, leptin is a life-saving therapy for
the rare children congenitally lacking the
hormone and of great benefit to many
more patients with lipodystrophy. We still
lack comparable transformative therapies
for commoner forms of obesity, however,
whichmay in part be becausemany of the
drug targets revealed by human genetics
are in the brain, making them difficult
to target. Nevertheless, I predict that
human genetic studies of outliers for
phenotypes such as extreme leanness
and retention of normal insulin sensitivity
despite massive obesity will be a fertile
ground for the discovery of new targets
of great therapeutic promise.Inc.Brain behind Feeding
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Over the last 20 years, the field of
obesity research has been revolutionized
through the identification of important
molecular pathways controlling energy
homeostasis. This was pioneered by the
identification of leptin as a fuel sensor
providing feedback information to the
CNS about energy availability in the
periphery of the organism to adapt food
intake and energy expenditure. This led
to the identification of critical neurons
that mediate the anorexigenic effects of
leptin and that at the same time orches-
trate multiple pathways in fuel homeo-
stasis, including glucose metabolism.
The recent developments in neuro-
circuitry mapping, including optoge-
netics, pharmacogenetics, and transla-
tional profiling of defined neurons,
provide the basis for a complete under-
standing of the complex neurocircuitry
controlling feeding, energy expenditure,
and peripheral glucose metabolism,
as well as the integration of these pro-
cesses with higher cognitive functions.
Defining the neuronal convergence
points of these regulatory pathways and
new modulators of this activity in my
view holds the potential to develop a
whole range of novel therapeutic targets
for metabolic disorders. Moreover, hav-
ing identified novel pathways involved in
obesity through genome-wide associa-
tion studies has revealed additional regu-
lators of energy homeostasis. Defining
their cellular and molecular actions will
potentially open novel therapeutic routes
as well. Collectively, we are facing an
exciting era in obesity research with
unprecedented promise for a deeper
understanding of its pathophysiology
and a plethora of unexpected therapeutic
options.
